
Ilya Tsimafeyeu/bucare.org
Jun 7, 2025, 05:44
Ilya Tsimafeyeu Presented Phase 2 SBRT Trial in Oligoprogressive Urothelial Cancer on Avelumab at ASCO 2025
Ilya Tsimafeyeu, Director at the Bureau of Cancer Research, shared a post on Facebook:
“Our randomized phase 2 study of stereotactic body radiation therapy in patients with oligoprogressive metastatic urothelial cancer receiving maintenance avelumab was announced at the Trials in Progress session at ASCO25.”
More posts featuring Ilya Tsimafeyeu on OncoDaily.
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
Highlights from ASCO 2025 Day 4
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 7, 2025, 14:53
Jun 7, 2025, 14:10
Jun 7, 2025, 12:23